在阿尔茨海默氏病中,粉样β的聚合机制和分子结构
Zheng Niu1, Xinrui Gui2, Shuang Feng1
1School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.
Chemistry (Weinheim an der Bergstrasse, Germany)
|June 18, 2024
概括
阿尔茨海默病涉及粉样β (Aβ) 斑块. 本综述探讨了Aβ聚合,液体液相分离 (LLPS) 和结构变异如何影响毒性和疾病进展.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 结构生物学 结构生物学
背景情况:
- 阿尔茨海默病的特点是粉样蛋白斑块,主要由粉样蛋白-β (Aβ) 组成.
- 亚β聚合是复杂的,形成多样化的结构,包括可以经历液体-液体相分离 (LLPS) 的寡合体.
- 粉样蛋白聚合与神经退行性疾病和压力颗粒有关.
研究的目的:
- 审查神经退行性疾病中压力颗粒和粉样蛋白聚合之间的关系.
- 突出LLPS在Aβ聚合中的监管作用及其与Aβ阶段过渡的联系.
- 总结当前的Aβ寡头和纤维结构及其对毒性和药物设计的影响.
主要方法:
- 文献综述侧重于粉样蛋白聚合和LLPS.
- 分析核磁共振 (NMR) 和冷电子显微镜 (cryo-EM) 的结构数据.
主要成果:
- Aβ寡合体的LLPS可能会调节粉样纤维的形成.
- 在Aβ聚合物的结构变化与不同的毒性水平相关.
- 核磁共振和冷EM已经阐明了Aβ寡合体和纤维的结构.
结论:
- 了解包括LLPS在内的Aβ聚合机制对于阿尔茨海默病研究至关重要.
- 对Aβ聚合物的结构洞察力可以解释毒性变异,并指导治疗策略.
- 基于结构的药物设计对阿尔茨海默氏症的诊断和治疗具有前景.
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179


